Skip to main content
Premium Trial:

Request an Annual Quote

Blue Cross Blue Shield Illinois to Cover Biocept Liquid Biopsy Assays

NEW YORK (GenomeWeb) – Biocept announced today that it has inked an agreement with Blue Cross Blue Shield of Illinois which gives members access to Biocept's menu of circulating tumor cell and circulating tumor DNA tests. 

According to Biocept, the addition of BCBS IL's more than 8 million members raises the number of patients with health insurance access to Biocept's liquid biopsy assays to approximately 133 million.

Biocept has steadily increased its menu of liquid biopsy assays over the last year and currently offers tests for alterations in a variety of cancer-associated genes. Its most recent addition is a CTC-based test for androgen receptor expression in prostate and breast cancer.

Michael Nall, president and CEO of Biocept, said in a statement that gaining coverage by individual health plans like BCBS IL is a key aspect of the company's reimbursement strategy.

The agreement with BCBS IL is also the company's first within the larger Blue Cross Blue Shield system. "We view this agreement as another indication of the growing awareness by healthcare providers of the important role liquid biopsy can have in the treatment of patients with cancer," Nall said.

In previous months Biocept has also announced agreements with the preferred provider networks Fortified Provider Network, Three Rivers Provider Network, Multiplan, Stratose, and Galaxy Health Network.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.